In summary, majority of reports show that CD204 correlates with good prognosis in prostate cancer and glioma, and with worse prognosis in colorectal cancer, cervical cancer, breast cancers, oral squamous cell carcinoma, lung cancer and prostate cancers. This evidence concerns the gene MSR1 and lung carcinoma.